236 related articles for article (PubMed ID: 24886624)
1. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
2. Selective control of gene expression by CDK9 in human cells.
Garriga J; Xie H; Obradovic Z; Graña X
J Cell Physiol; 2010 Jan; 222(1):200-8. PubMed ID: 19780058
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.
Salerno D; Hasham MG; Marshall R; Garriga J; Tsygankov AY; Graña X
Gene; 2007 Dec; 405(1-2):65-78. PubMed ID: 17949927
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
5. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
6. Complex effects of flavopiridol on the expression of primary response genes.
Keskin H; Garriga J; Georlette D; Graña X
Cell Div; 2012 Mar; 7():11. PubMed ID: 22458775
[TBL] [Abstract][Full Text] [Related]
7. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription.
Ou M; Sandri-Goldin RM
PLoS One; 2013; 8(10):e79007. PubMed ID: 24205359
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA.
Burger K; Mühl B; Rohrmoser M; Coordes B; Heidemann M; Kellner M; Gruber-Eber A; Heissmeyer V; Strässer K; Eick D
J Biol Chem; 2013 Jul; 288(29):21173-21183. PubMed ID: 23744076
[TBL] [Abstract][Full Text] [Related]
11. The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.
Oqani RK; Kim HR; Diao YF; Park CS; Jin DI
BMC Dev Biol; 2011 Jun; 11():33. PubMed ID: 21639898
[TBL] [Abstract][Full Text] [Related]
12. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
[TBL] [Abstract][Full Text] [Related]
13. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of P-TEFb disrupts global transcription, oocyte maturation, and embryo development in the mouse.
Oqani RK; Lin T; Lee JE; Kim SY; Sa SJ; Woo JS; Jin DI
Genesis; 2016 Sep; 54(9):470-82. PubMed ID: 27488304
[TBL] [Abstract][Full Text] [Related]
15. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription.
Zhou M; Deng L; Lacoste V; Park HU; Pumfery A; Kashanchi F; Brady JN; Kumar A
J Virol; 2004 Dec; 78(24):13522-33. PubMed ID: 15564463
[TBL] [Abstract][Full Text] [Related]
16. CDK9 as an Appealing Target for Therapeutic Interventions.
Eyvazi S; Hejazi MS; Kahroba H; Abasi M; Zamiri RE; Tarhriz V
Curr Drug Targets; 2019; 20(4):453-464. PubMed ID: 30362418
[TBL] [Abstract][Full Text] [Related]
17. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
Gordon V; Bhadel S; Wunderlich W; Zhang J; Ficarro SB; Mollah SA; Shabanowitz J; Hunt DF; Xenarios I; Hahn WC; Conaway M; Carey MF; Gioeli D
Mol Endocrinol; 2010 Dec; 24(12):2267-80. PubMed ID: 20980437
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).
Chiu YL; Cao H; Jacque JM; Stevenson M; Rana TM
J Virol; 2004 Mar; 78(5):2517-29. PubMed ID: 14963154
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
20. CDK9 keeps RNA polymerase II on track.
Egloff S
Cell Mol Life Sci; 2021 Jul; 78(14):5543-5567. PubMed ID: 34146121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
